Immune Design Corp. (NASDAQ:IMDZ) Director Lewis W. Coleman purchased 40,000 shares of the business’s stock in a transaction on Tuesday, September 20th. The stock was bought at an average cost of $6.25 per share, for a total transaction of $250,000.00. Following the purchase, the director now owns 50,000 shares of the company’s stock, valued at approximately $312,500. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of Immune Design Corp. (NASDAQ:IMDZ) opened at 7.52 on Thursday. The stock has a 50 day moving average of $7.07 and a 200-day moving average of $10.24. Immune Design Corp. has a 12 month low of $6.02 and a 12 month high of $23.55. The company’s market cap is $151.72 million.

Immune Design Corp. (NASDAQ:IMDZ) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.03. Immune Design Corp. had a negative return on equity of 44.57% and a negative net margin of 525.30%. On average, analysts forecast that Immune Design Corp. will post ($2.70) EPS for the current year.

Institutional investors have recently modified their holdings of the company. RS Investment Management Co. LLC boosted its position in shares of Immune Design Corp. by 3.2% in the second quarter. RS Investment Management Co. LLC now owns 1,227,595 shares of the company’s stock worth $10,017,000 after buying an additional 38,123 shares in the last quarter. Pictet Asset Management Ltd. boosted its position in shares of Immune Design Corp. by 768.9% in the second quarter. Pictet Asset Management Ltd. now owns 748,145 shares of the company’s stock valued at $9,389,000 after buying an additional 662,045 shares during the period. Vanguard Group Inc. boosted its position in shares of Immune Design Corp. by 2.4% in the second quarter. Vanguard Group Inc. now owns 334,933 shares of the company’s stock valued at $2,734,000 after buying an additional 7,941 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Immune Design Corp. by 72.6% in the second quarter. JPMorgan Chase & Co. now owns 246,675 shares of the company’s stock valued at $2,014,000 after buying an additional 103,750 shares during the period. Finally, State Street Corp boosted its position in shares of Immune Design Corp. by 23.5% in the second quarter. State Street Corp now owns 207,670 shares of the company’s stock valued at $1,694,000 after buying an additional 39,551 shares during the period. Institutional investors own 48.03% of the company’s stock.

A number of analysts have recently commented on the stock. Zacks Investment Research raised shares of Immune Design Corp. from a “sell” rating to a “hold” rating in a research report on Friday, August 12th. Jefferies Group reissued a “buy” rating and issued a $17.00 price objective (down previously from $20.00) on shares of Immune Design Corp. in a research report on Wednesday, August 10th. Finally, Leerink Swann reissued a “buy” rating on shares of Immune Design Corp. in a research report on Friday, June 10th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Immune Design Corp. currently has an average rating of “Buy” and an average price target of $14.50.

About Immune Design Corp.

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

5 Day Chart for NASDAQ:IMDZ

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.